VEGFA and hepatocellular carcinoma: While immune checkpoint blockade strategies (alone or in combination with TME modifying anti-VEGF therapy) that attempt to restore the in vivo HCC-specific T-cell function can potentially modify the TME as well, the frequent replenishment of T cells recognizing HCC in the patient has a potential advantage in terms of the TME modifying capacity.